Clinical Outcomes in Patients With Colon Cancer With Microsatellite Instability of Sporadic or Familial Origin Treated With Adjuvant FOLFOX With or Without Cetuximab: A Pooled Analysis of the PETACC8 and N0147 Trials.

The microsatellite instability (MSI) or deficient mismatch repair (dMMR) phenotype is usually regarded as a single biologic entity, given the absence of comparative analyses regarding prognosis and response to chemotherapy between sporadic and familial dMMR cancers. Patients with stage III colon cancers were randomly assigned to FOLFOX (leucovorin, fluorouracil, and oxaliplatin) with or without cetuximab in 2 large adjuvant phase III trials (N = 5,577). Among patients with MSI and Among patients with MSI status with complete data for dMMR mechanism analysis (n = 354), 255 (72%) had sporadic ( The addition of cetuximab to adjuvant FOLFOX was associated with shorter DFS in patients with sporadic dMMR colon cancer. Additional studies are needed to validate these results in metastatic disease.

Informations de copyright

© 2020 by American Society of Clinical Oncology.

Déclaration de conflit d'intérêts

The following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated unless otherwise noted. Relationships are self-held unless noted. I = Immediate Family Member, Inst = My Institution. Relationships may not relate to the subject matter of this manuscript. For more information about ASCO's conflict of interest policy, please refer to www.asco.org/rwc or ascopubs.org/po/author-center. Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments). Aziz ZaananConsulting or Advisory Role: Amgen, Eli Lilly, Merck Serono, Roche, Sanofi, Merck Sharp & Dohme, Servier, Baxter Research Funding: AmgenJulien TaiebConsulting or Advisory Role: Roche, Merck, Amgen, Celgene, Eli Lilly, Servier, Sirtex Medical, Merck Sharp & Dohme, Pierre Fabre Speakers’ Bureau: Servier, Amgen, Roche/Genentech, Sanofi, Merck, Eli Lilly, Merck Sharp & Dohme, Pierre FabreCatherine JulieHonoraria: Novartis Travel, Accommodations, Expenses: Bristol-Myers SquibbJosep TaberneroConsulting or Advisory Role: Bayer, Boehringer Ingelheim, Eli Lilly, Merck Sharp & Dohme, Merck Serono, Novartis, Sanofi, Taiho Pharmaceutical, Merrimack, Peptomyc, Rafael Pharmaceuticals, Symphogen, Chugai Pharma, Ipsen, Merus, Pfizer, Seattle Genetics, Array BioPharma, AstraZeneca, BeiGene, Genentech, Genmab, Halozyme, Imugene, Inflection Biosciences, Kura, Menarini, Molecular Partners, Pharmacyclics, ProteoDesign, Roche, Servier, VCN Biosciences, Biocartis, Foundation Medicine, HalioDX SAS, Roche DiagnosticsRichard M. GoldbergHonoraria: Amgen Consulting or Advisory Role: Merck, Taiho Pharmaceutical, Merck, Novartis Research Funding: Bristol-Myers Squibb Travel, Accommodations, Expenses: Merck, AmgenGunnar FolprechtHonoraria: Merck, Eli Lilly/ImClone, Roche/Genentech, Bristol-Myers Squibb, Sanofi/Aventis, Servier, Merck Sharp & Dohme Consulting or Advisory Role: Roche/Genentech, Merck, Bristol-Myers Squibb, Sanofi/Aventis, Bayer, Mundipharma, Servier, Merck Sharp & Dohme, Amgen Research Funding: MerckPierre Laurent-PuigHonoraria: Amgen, AstraZeneca, Boehringer Ingelheim, Merck Serono, Merck, Roche, Sanofi, Biocartis, MSD Oncology, Bristol-Myers Squibb Consulting or Advisory Role: Merck, Bristol-Myers Squibb, Boehringer Ingelheim Patents, Royalties, Other Intellectual Property: Inventor of mir31-3p license to IntegraGen Travel, Accommodations, Expenses: Roche, MerckFrank A. SinicropeStock and Other Ownership Interests: Illumina Honoraria: Imedex, American Society of Clinical Oncology Consulting or Advisory Role: Roche (Inst), Bristol-Myers Squibb (Inst), Ventana Medical Systems (Inst), HalioDx (Inst) Research Funding: Ventana Medical Systems (Inst) Travel, Accommodations, Expenses: Ventana Medical Systems No other potential conflicts of interest were reported.